| ID | 1016 |
| Name of the vaccine | Tenivac |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 7 years and older |
| Description of the vaccine | Tetanus and diphtheria toxoids adsorbed (Td vaccine). |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2003 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Primary Immunization - Three 0.5 mL doses.
Routine Booster- Recommended in children 11-12 years of age and every 10 years. |
| Mechanism of action | Serum diphtheria antitoxin level of at least of 1.0 IU/mL is for long-term protection. |
| Route of administration | Intramuscular |
| Indications | Active immunization for the prevention of tetanus and diphtheria. |
| Export | Distributed by Sanofi Pasteur Inc, USA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For tetanus also. |
| Side effects of vaccine | Pain, headache, injection site redness, swelling, malaise, muscle weakness and pain in joints. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/76610/download |
| Other name | NA |
| Additional Links | NA
|